Abstract
In addition to well-established genetic abnormalities -particularly gene mutations, deletions or translocations -, epigenetic abnormalities are also implicated in the development and progression of hematological malignancies. As such, the constitutive pattern of DNA methylation and histone acetylation observed in normal hematopoietic cells is remarkably altered in both myeloid and lymphoid tumors. Recent advances in the understanding of these transcriptional and post-transcriptional mechanisms in normal B and T cells as well as malignant lymphoid cells have been instrumental in the development of novel diagnostic markers, prognostic classification and targeted therapeutic approaches. This review focuses on the most important epigenetic alterations discovered in lymphoma-derived cell lines and primary lymphoid tumors and how pharmacologic manipulation of these abnormalities could eventually change the way we treat them in the clinic.
Keywords: DNA methylation, Histone acetylation, Demethylating agents, Histone deacetylase inhibitors, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Chronic lymphocytic leukemia
Current Cancer Drug Targets
Title: Novel Epigenetic Targets in Lymphoproliferative Disorders
Volume: 8 Issue: 5
Author(s): Julio Delgado
Affiliation:
Keywords: DNA methylation, Histone acetylation, Demethylating agents, Histone deacetylase inhibitors, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Chronic lymphocytic leukemia
Abstract: In addition to well-established genetic abnormalities -particularly gene mutations, deletions or translocations -, epigenetic abnormalities are also implicated in the development and progression of hematological malignancies. As such, the constitutive pattern of DNA methylation and histone acetylation observed in normal hematopoietic cells is remarkably altered in both myeloid and lymphoid tumors. Recent advances in the understanding of these transcriptional and post-transcriptional mechanisms in normal B and T cells as well as malignant lymphoid cells have been instrumental in the development of novel diagnostic markers, prognostic classification and targeted therapeutic approaches. This review focuses on the most important epigenetic alterations discovered in lymphoma-derived cell lines and primary lymphoid tumors and how pharmacologic manipulation of these abnormalities could eventually change the way we treat them in the clinic.
Export Options
About this article
Cite this article as:
Delgado Julio, Novel Epigenetic Targets in Lymphoproliferative Disorders, Current Cancer Drug Targets 2008; 8 (5) . https://dx.doi.org/10.2174/156800908785133222
DOI https://dx.doi.org/10.2174/156800908785133222 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Overview of Antiangiogenic Therapies in Hematological Malignancies (Guest Editor: D. Ribatti)]
Current Cancer Drug Targets Towards Cure of CML: Why We Need to Know More About CML Stem Cells?
Current Stem Cell Research & Therapy Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Antithrombotic Treatment in the Prevention of Ischemic Stroke
Current Drug Targets Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Impact of the Somatotrope Growth Hormone (GH)/Insulin-Like Growth Factor 1 (IGF-1) Axis Upon Thymus Function: Pharmacological Implications in Regeneration of Immune Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Interstitial Lung Disease in Sjogrens Syndrome
Current Rheumatology Reviews Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Synthesis, Characterization and Theoretical Studies of Novel Phosphonates as uPA Inhibitors
Current Organic Chemistry Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
Current Clinical Pharmacology Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Current Drug Discovery Technologies Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry Chemopreventive and Anti-leukemic Effects of Ethanol Extracts of Moringa oleifera Leaves on Wistar Rats Bearing Benzene Induced Leukemia
Current Pharmaceutical Biotechnology